GINKGO BIOWORKS HOLDINGS INC CLASS (DNA)
Health Care · NYSE
Ginkgo Bioworks engineers biology at scale through lab automation, AI-driven R&D services, and biosecurity infrastructure to help customers develop new therapeutics, vaccines, industrial chemicals, and biological threat detection.
What GINKGO BIOWORKS HOLDINGS INC CLASS does
Ginkgo Bioworks is a platform-based biotechnology company offering cell engineering R&D services, tools, and biosecurity solutions to government and commercial customers. Through its Autonomous Lab—powered by Reconfigurable Automation Carts and AI/ML software—the company enables faster, more cost-effective biological product development across medicine, agriculture, industrial biotech, and defense sectors. The company also provides biosecurity services to help identify, monitor, and prevent biological threats in response to pandemic and bioterror risks.
Themes: ["Synthetic biology / cell engineering"]
Fundamentals
- Price$9.73 as of 2026-07-09 close
- Market cap$636M as of 2026-07-10
- 1-year return-12.1% as of 2026-07-09 close
- Net margin-215.4% as of 2026-07-10
- Gross margin+73.1% as of 2026-07-10
- ROE-57.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-40.5% as of 2026-07-10
- Revenue CAGR (3y)-29.1% SEC XBRL
- Beta1.75 as of 2026-07-10
Key risks (from latest filing)
["Severe revenue decline (-40.48% YoY) with significant operating losses (-215.41% net margin), indicating inability to achieve profitability and potential runway concerns despite $143.9M cash on hand."]
Competitors & peers
- Zymergen
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.